Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
Holding INSM?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$1.18Last Year’s EPS
-$1.28Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: 0.33%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call was generally positive, highlighting significant sales growth, a strong financial position, and progress in drug development. However, concerns about increased cash burn and uncertainties regarding regulatory approvals were noted.Company Guidance
During the Insmed Third Quarter 2024 Financial Results Conference Call, the company provided guidance indicating strong financial performance and strategic growth initiatives. The company reported a remarkable global net revenue of $93.4 million in Q3, reflecting an 18% year-over-year growth, with ARIKAYCE achieving its highest quarterly sales ever. Insmed's robust financial position was reinforced by utilizing their ATM equity offering program, raising approximately $371 million, and restructuring their $350 million term loan with Pharmakon, securing an additional $150 million in proceeds and reducing the interest rate to a fixed 9.6%. The company remains on track to meet its full-year revenue guidance of $340 million to $360 million. Additionally, Insmed is preparing for the launch of brensocatib in mid-2025 by tripling its U.S. sales force, now totaling 184 representatives, and is progressing with its NDA filing for brensocatib expected in Q4. The company continues to advance its pipeline, including the Phase II BiRCh study in chronic rhinosinusitis without nasal polyps, now over 40% enrolled, and the CEDAR study in hidradenitis suppurativa, expected to enroll approximately 204 subjects.Double-Digit Sales Growth for ARIKAYCE
The commercial team delivered double-digit year-over-year sales growth for ARIKAYCE across all regions, marking the seventh consecutive quarter of such growth.
Strong Financial Position
Insmed improved its financial position by restructuring a term loan with Pharmakon, raising $371 million through an ATM, and calling $225 million convertible notes, leading to an increase in cash to $1.5 billion.
Progress in Brensocatib Development
The company is on track to file the NDA for brensocatib in the U.S. this quarter, with significant advancements in its Phase II and Phase III studies across various indications.
Record Quarterly Revenue
Insmed achieved the highest quarterly sales for ARIKAYCE in its history, with global net revenue reaching $93.4 million, an 18% year-over-year increase.
Expansion of U.S. Sales Force
The company nearly tripled its U.S. sales force in preparation for the expected brensocatib launch, with a total of 184 sales reps now deployed.
---
INSM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INSM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $70.30 | $67.28 | -4.30% |
| Aug 08, 2024 | $70.99 | $71.81 | +1.16% |
| May 09, 2024 | $26.00 | $26.38 | +1.46% |
| Feb 22, 2024 | $28.24 | $27.15 | -3.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Insmed (INSM) report earnings?
Insmed (INSM) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Insmed (INSM) earnings time?
Insmed (INSM) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INSM EPS forecast?
INSM EPS forecast for the fiscal quarter 2024 (Q4) is -$1.18.
---